
MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia
Author(s) -
Fengchang Bao,
Lei Zhang,
Xiaohang Pei,
Cheng Lian,
Qing Liu,
Hongna Tan,
Pingchong Lei
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0256995
Subject(s) - cancer research , myeloid leukemia , cell cycle , oncogene , cell growth , apoptosis , gene knockdown , flow cytometry , leukemia , bone marrow , biology , medicine , immunology , biochemistry , genetics
Acute myeloid leukemia (AML) is as a highly aggressive and heterogeneous hematological malignancy. MiR-20a-5p has been reported to function as an oncogene or tumor suppressor in several tumors, but the clinical significance and regulatory mechanisms of miR-20a-5p in AML cells have not been fully understood. In this study, we found miR-20a-5p was significantly decreased in bone marrow from AML patients, compared with that in healthy controls. Moreover, decreased miR-20a-5p expression was correlated with risk status and poor survival prognosis in AML patients. Overexpression of miR-20a-5p suppressed cell proliferation, induced cell cycle G0/G1 phase arrest and apoptosis in two AML cell lines (THP-1 and U937) using CCK-8 assay and flow cytometry analysis. Moreover, miR-20a-5p overexpression attenuated tumor growth in vivo by performing tumor xenograft experiments. Luciferase reporter assay and western blot demonstrated that protein phosphatase 6 catalytic subunit ( PPP6C ) as a target gene of miR-20a-5p was negatively regulated by miR-20a-5p in AML cells. Furthermore, PPP6C knockdown imitated, while overexpression reversed the effects of miR-20a-5p overexpression on AML cell proliferation, cell cycle G1/S transition and apoptosis. Taken together, our findings demonstrate that miR-20a-5p / PPP6C represent a new therapeutic target for AML and a potential diagnostic marker for AML therapy.